目的:了解酒钢医院(以下简称"我院")住院患者保肝药的临床应用情况及趋势,为临床合理用药提供参考.方法:采用销售金额排序法、用药频度排序法对2014-2016年我院住院患者保肝药的临床应用情况进行统计分析.结果:2014-2016年我院住院患者销售金额排序居第1位的保肝药为注射用门冬氨酸鸟氨酸,DDDs排序居第1、2位的保肝药为注射用门冬氨酸鸟氨酸和熊去氧胆酸片.其原因主要与注射用门冬氨酸鸟氨酸价格较高、无适应证用药频次较高,而熊去氧胆酸片在消化系统疾病中应用广泛有关.结论:我院住院患者保肝药的使用欠合理,有待进一步加强管理和干预,促进合理用药.%OBJECTIVE:To investigate the application and its trend of hepatic protectors on inpatients in Jiugang Hospital (hereinafter referred to as "our hospital"), and provide references for clinical rational drug application. METHODS:Consumption sum ranking and defined daily dose system (DDDs) ranking were adopted to analyze the clinical application of hepatic protectors on inpatients in our hospital during 2014-2016. RESULTS:During 2014-2016, the top 1 hepatic protector ranked by consumption sum in inpatients in our hospital was Ornithine Aspartate for Injection, the top 2 hepatic protectors ranked by DDDs were Ornithine Aspartate for Injection and Ursodesoxycholic acid tablets, which mainly because of the high price and high DDDs without indication of Ornithine Aspartate for Injection, and the wide application of Ursodesoxycholic acid in digestive system diseases tablets. CONCLUSIONS:The application of hepatic protector on inpatients in our hospital is less rational, further administration and intervention should be reinforced to promote rational drug application.
展开▼
